- Several health systems and insurers recently indicated they would not cover or offer Aduhelm, a list that includes the Department of Veterans Affairs, Boston-based Mass General Brigham and eight Blue Cross Blue Shield affiliates.
- Biogen reported $300,000 in Aduhelm sales in its third-quarter financial report released Oct. 20. At a price of $56,000 per year, this is much less than many analysts expected.
- Biogen on Nov. 8 launched an investigation into the death of a 75-year-old patient potentially linked to Aduhelm.
- CMS announced Nov. 13 Medicare Part B premiums and deductibles will see the largest hike in the program’s history next year. The agency said one of the key reasons for this is the potential need to cover the high cost of Aduhelm.
- Biogen said Nov. 15 that its head of research and development, Alfred Sandrock, MD, PhD, will leave the company after 23 years. He is the drugmaker’s top scientist and led its yearslong effort to develop and commercialize Aduhelm.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
